Prelude Therapeutics Inc. (PRLD) News

Prelude Therapeutics Inc. (PRLD): $4.09

0.05 (+1.24%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add PRLD to Watchlist
Sign Up

Filter PRLD News Items

PRLD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PRLD News Highlights

  • PRLD's 30 day story count now stands at 2.
  • Over the past 13 days, the trend for PRLD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • LNG, DEC and SHEL are the most mentioned tickers in articles about PRLD.

Latest PRLD News From Around the Web

Below are the latest news stories about PRELUDE THERAPEUTICS INC that investors may wish to consider to help them evaluate PRLD as an investment opportunity.

AI Meets Biotech: 3 Top Stocks Transforming Medical Science

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.

John Blankenhorn on InvestorPlace | December 16, 2023

Prelude Therapeutics Announces $25 Million Private Placement

WILMINGTON, Del., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced a private placement that the Company estimates will result in gross proceeds of approximately $25 million before deducting estimated offering expenses payable by the Company. Proceeds from the private placement will be used to primarily fund the continued advancement of its SMARCA2 portfolio, for working ca

Yahoo | December 11, 2023

Shell's (SHEL) Prelude LNG Facility to Restart in December

Shell's (SHEL) Prelude LNG facility, nearing the completion of extensive maintenance, is poised for a strategic comeback, aiding the global LNG market.

Yahoo | November 28, 2023

Prelude Therapeutics Insiders Are Down US$149k But Regain Some Losses

Insiders who bought US$263.0k worth of Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) stock in the last year have...

Yahoo | November 5, 2023

Q3 2023 Abcellera Biologics Inc Earnings Call

Q3 2023 Abcellera Biologics Inc Earnings Call

Yahoo | November 3, 2023

Prelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline Progress

Company prioritizes SMARCA2 degrader and CDK9 inhibitor programs, reports cash runway into 2026

Yahoo | November 3, 2023

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Prioritization of its first-in-class SMARCA2 degrader and potentially best-in-class CDK9 inhibitor programs for continued clinical development Enters partnership with AbCellera to develop a portfolio of precision ADCs with first program being a SMARCA degrader-antibody conjugate Cash runway into 2026 with $230.5 million of cash, cash equivalents and marketable securities WILMINGTON, Del., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-sta

Yahoo | November 1, 2023

Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

WILMINGTON, Del. & VANCOUVER, British Columbia, November 01, 2023--Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology

Yahoo | November 1, 2023

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

WILMINGTON, Del. and BOSTON, Oct. 14, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude”) (Nasdaq: PRLD), a clinical-stage precision oncology company, announces multiple clinical and preclinical posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11 - 15, 2023 at the Hynes Convesntion Center in Boston, MA. The four Prelude poster presentations include data from two ongoing Phase 1 clinic

Yahoo | October 14, 2023

All You Need to Know About Prelude Therapeutics Incorporated (PRLD) Rating Upgrade to Buy

Prelude Therapeutics Incorporated (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | October 4, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!